Lichtenstein-Knorr Syndrome

Mendelian MONDO:0014572 Pathograph 15 Show in embeddings browser Autosomal Recessive Cerebellar Ataxia Mendelian Disease

Lichtenstein-Knorr syndrome (LIKNS; SCAR19) is a very rare autosomal recessive neurodegenerative disorder that associates progressive cerebellar ataxia with severe progressive sensorineural hearing loss. It is caused by biallelic loss-of-function variants in SLC9A1, which encodes NHE1 (sodium/hydrogen exchanger isoform 1), the major plasma-membrane Na+/H+ exchanger. NHE1 maintains intracellular pH homeostasis by exchanging one intracellular proton for one extracellular sodium ion. The founding family carried a homozygous p.Gly305Arg missense mutation that causes near-complete de-glycosylation, mistargeting, and loss of proton-pumping activity of NHE1; subsequent families carry truncating variants. Loss of NHE1 function dysregulates intracellular pH in the central nervous system, producing selective neuronal vulnerability (cerebellar/Purkinje neurons and cochlear hair cells), recapitulated by the spontaneous and knockout Slc9a1 ("swe", slow-wave epilepsy) mouse models that show ataxia, seizures, and selective neuronal cell death. Deafness is variable and may be absent in some SLC9A1-mutated patients, so it may not be an essential phenotypic feature. Management is supportive (hearing aids or cochlear implantation, rehabilitation, and seizure control).

Ask OpenScientist

Ask a research question about Lichtenstein-Knorr Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

⚙

Pathophysiology

SLC9A1 (NHE1) loss of function

Biallelic SLC9A1 variants cause loss of function of NHE1, the major plasma-membrane sodium/hydrogen exchanger. In the founding consanguineous family the homozygous p.Gly305Arg (c.913G>A) missense variant, affecting a highly conserved residue in the eighth transmembrane segment, causes near-complete de-glycosylation, mistargeting, and loss of proton-pumping activity of NHE1; truncating variants such as p.Ile288Serfs*9 also cause disease.

SLC9A1 hgnc:11071

sodium:proton antiporter activity GO:0015385 ↓ DECREASED

Downstream

Impaired intracellular pH homeostasis Loss of NHE1 proton extrusion directly impairs regulation of intracellular pH.

Show evidence (3 references)

PMID:25205112 SUPPORT Human Clinical

"we identified the homozygous p.Gly305Arg missense mutation in SLC9A1 that segregates with the disease in a large consanguineous family"

Identifies SLC9A1 as the disease gene with a homozygous missense mutation segregating in the affected family.

PMID:25205112 SUPPORT In Vitro

"We demonstrate that the p.Gly305Arg mutation causes the near complete de-glycosylation, mis-targeting and loss of proton pumping activity of NHE1."

Functional assays demonstrate the variant abolishes NHE1 proton-pumping activity, establishing loss of function.

PMID:30018422 SUPPORT Human Clinical

"we identified a novel homozygous SLC9A1 truncating mutation, c.862del (p.Ile288Serfs*9), in two affected siblings"

Documents an additional biallelic truncating SLC9A1 variant causing the disorder, supporting a loss-of-function mechanism.

Impaired intracellular pH homeostasis

NHE1 maintains intracellular pH by exchanging one intracellular proton for one extracellular sodium ion. Loss of NHE1 function leads to dysregulated intracellular pH, which is especially deleterious in the central nervous system.

neuron CL:0000540

regulation of intracellular pH GO:0051453 ⚠ ABNORMAL

Downstream

Selective neuronal vulnerability and neurodegeneration Dysregulated intracellular pH produces selective vulnerability and death of cerebellar neurons and cochlear hair cells.

Show evidence (2 references)

PMID:30018422 SUPPORT Human Clinical

"NHE1 plays an important role in maintaining intracellular pH homeostasis by exchanging one intracellular proton for one extracellular sodium ion."

Establishes the molecular role of NHE1 in intracellular pH homeostasis that is lost in this disease.

PMID:25205112 SUPPORT Human Clinical

"the association between ataxia and hearing loss is caused by complete or near complete loss of function of NHE1 and altered regulation of pHi in the central nervous system"

Links loss of NHE1 function and altered intracellular pH regulation in the CNS to the ataxia-deafness phenotype.

Selective neuronal vulnerability and neurodegeneration

Loss of NHE1-dependent pH regulation produces selective neuronal cell death. The cerebellum (including Purkinje cells) and the cochlea (sensory hair cells) are particularly vulnerable, producing progressive cerebellar ataxia and sensorineural hearing loss. The spontaneous and knockout Slc9a1 (Nhe1) mouse models recapitulate ataxia, recurrent seizures, and selective neuronal cell death.

cerebellar Purkinje cell CL:0000121 cochlear hair cell CL:4023120

Downstream

Cerebellar ataxia Cerebellar neurodegeneration produces progressive cerebellar ataxia.

Sensorineural hearing impairment Cochlear hair cell vulnerability produces progressive sensorineural hearing loss.

Cerebellar atrophy Progressive cerebellar neuronal loss produces cerebellar atrophy on neuroimaging.

Dysarthria Cerebellar neurodegeneration can produce dysarthria as part of the progressive ataxia syndrome.

Nystagmus Cerebellar neurodegeneration can produce nystagmus as an oculomotor sign of the ataxia syndrome.

Seizures Slc9a1/NHE1 loss can produce recurrent seizures in the NHE1-loss phenotype spectrum.

Show evidence (2 references)

PMID:30018422 SUPPORT Model Organism

"Mice with a homozygous null mutation in Slc9a1 (Nhe1) exhibited ataxia, recurrent seizures, and selective neuronal cell death."

The Slc9a1-null mouse model demonstrates that NHE1 loss causes ataxia, seizures, and selective neuronal degeneration.

PMID:25205112 SUPPORT Model Organism

"The comparison of our family with the phenotypes of spontaneous and knockout Slc9a1 murine models"

Phenotypic comparison with spontaneous and knockout Slc9a1 mouse models supports neurodegeneration as the mechanism linking the human phenotype to NHE1 loss.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Ear 1

Sensorineural hearing impairment Sensorineural hearing impairment HP:0000407

Course: PROGRESSIVE

Show evidence (2 references)

PMID:25205112 SUPPORT Human Clinical

"Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."

Defines sensorineural hearing loss as a core feature of the syndrome.

PMID:30018422 PARTIAL Human Clinical

"deafness may not be an essential phenotypic feature of SLC9A1 mutation"

Notes that hearing loss, while characteristic, is variable and may be absent in some SLC9A1-mutated patients.

Eye 1

Nystagmus Nystagmus HP:0000639

Show evidence (1 reference)

PMID:25205112 PARTIAL Human Clinical

"Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."

Nystagmus is a cerebellar oculomotor sign within the ataxia syndrome described; this evidence supports the cerebellar syndrome of which nystagmus is a component.

Nervous System 4

Cerebellar ataxia Ataxia HP:0001251

Course: PROGRESSIVE

Show evidence (2 references)

PMID:25205112 SUPPORT Human Clinical

"Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."

Defines cerebellar ataxia as a core feature of the syndrome.

PMID:30018422 SUPPORT Human Clinical

"The patients showed cerebellar ataxia but neither of them showed sensorineural hearing loss nor a neuromuscular phenotype."

A second family confirms cerebellar ataxia as a consistent feature of SLC9A1-related disease.

Cerebellar atrophy Cerebellar atrophy HP:0001272

Show evidence (1 reference)

PMID:30018422 PARTIAL Model Organism

"Mice with a homozygous null mutation in Slc9a1 (Nhe1) exhibited ataxia, recurrent seizures, and selective neuronal cell death."

Selective cerebellar neuronal cell death in the Slc9a1-null mouse underlies the cerebellar atrophy seen in patients; direct human cerebellar atrophy is documented in the disease's clinical descriptions (MONDO/OMIM).

Dysarthria Dysarthria HP:0001260

Show evidence (1 reference)

PMID:25205112 PARTIAL Human Clinical

"Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."

Dysarthria is a cerebellar sign within the ataxia syndrome described; this evidence supports the cerebellar syndrome of which dysarthria is a component.

Seizures Seizure HP:0001250

Show evidence (1 reference)

PMID:30018422 PARTIAL Model Organism

"Mice with a homozygous null mutation in Slc9a1 (Nhe1) exhibited ataxia, recurrent seizures, and selective neuronal cell death."

The Slc9a1-null mouse exhibits recurrent seizures, supporting seizures as part of the NHE1-loss phenotype spectrum; classified MODEL_ORGANISM as the quoted evidence is from mice.

🧬

Genetic Associations

SLC9A1 variants

Gene: SLC9A1 hgnc:11071

Autosomal recessive

Show evidence (1 reference)

PMID:30018422 SUPPORT Human Clinical

"c.913G>A (p.Gly305Arg), which caused Lichtenstein-Knorr syndrome characterized by cerebellar ataxia and sensorineural hearing loss"

Confirms the SLC9A1 p.Gly305Arg genotype-phenotype relationship for Lichtenstein-Knorr syndrome.

💊

Medical Actions

Hearing Rehabilitation

Action: hearing aid usage MAXO:0009030

Hearing aids and, for severe-to-profound sensorineural hearing loss, cochlear implantation are used to address the progressive deafness component.

Target Phenotypes: Sensorineural hearing impairment HP:0000407

Show evidence (1 reference)

PMID:25205112 PARTIAL Human Clinical

"Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."

The hearing-loss component supports auditory rehabilitation as supportive management; no disease-modifying therapy exists.

Cochlear Implantation

Action: cochlear device implantation MAXO:0009025

Cochlear implantation is an option for severe-to-profound sensorineural hearing loss not adequately addressed by hearing aids.

Target Phenotypes: Sensorineural hearing impairment HP:0000407

Show evidence (1 reference)

PMID:25205112 PARTIAL Human Clinical

"Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."

The severe progressive sensorineural hearing loss supports cochlear implantation as a management option; this is supportive, not disease-modifying.

Supportive and Rehabilitative Care

Action: supportive care MAXO:0000950

No disease-modifying therapy exists. Management is supportive, including physiotherapy and occupational therapy for ataxia, mobility aids, and seizure control where present.

Target Phenotypes: Ataxia HP:0001251 Seizure HP:0001250

Show evidence (1 reference)

PMID:25205112 PARTIAL Human Clinical

"Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."

The progressive ataxia and associated neurologic features warrant supportive and rehabilitative care; no targeted treatment is established.

{ }

Source YAML

click to show

name: Lichtenstein-Knorr Syndrome
creation_date: "2026-06-04T12:00:00Z"
category: Mendelian
synonyms:
- LIKNS
- SCAR19
- Spinocerebellar ataxia, autosomal recessive 19
- SLC9A1-related spinocerebellar ataxia syndrome
- Ataxia-deafness Lichtenstein-Knorr syndrome
- Progressive autosomal recessive ataxia-sensorineural hearing loss syndrome
description: >
  Lichtenstein-Knorr syndrome (LIKNS; SCAR19) is a very rare autosomal recessive
  neurodegenerative disorder that associates progressive cerebellar ataxia with
  severe progressive sensorineural hearing loss. It is caused by biallelic
  loss-of-function variants in SLC9A1, which encodes NHE1 (sodium/hydrogen
  exchanger isoform 1), the major plasma-membrane Na+/H+ exchanger. NHE1
  maintains intracellular pH homeostasis by exchanging one intracellular proton
  for one extracellular sodium ion. The founding family carried a homozygous
  p.Gly305Arg missense mutation that causes near-complete de-glycosylation,
  mistargeting, and loss of proton-pumping activity of NHE1; subsequent families
  carry truncating variants. Loss of NHE1 function dysregulates intracellular pH
  in the central nervous system, producing selective neuronal vulnerability
  (cerebellar/Purkinje neurons and cochlear hair cells), recapitulated by the
  spontaneous and knockout Slc9a1 ("swe", slow-wave epilepsy) mouse models that
  show ataxia, seizures, and selective neuronal cell death. Deafness is variable
  and may be absent in some SLC9A1-mutated patients, so it may not be an
  essential phenotypic feature. Management is supportive (hearing aids or
  cochlear implantation, rehabilitation, and seizure control).
disease_term:
  preferred_term: Lichtenstein-Knorr Syndrome
  term:
    id: MONDO:0014572
    label: Lichtenstein-Knorr syndrome
parents:
- Autosomal Recessive Cerebellar Ataxia
- Mendelian Disease
pathophysiology:
- name: SLC9A1 (NHE1) loss of function
  description: >
    Biallelic SLC9A1 variants cause loss of function of NHE1, the major
    plasma-membrane sodium/hydrogen exchanger. In the founding consanguineous
    family the homozygous p.Gly305Arg (c.913G>A) missense variant, affecting a
    highly conserved residue in the eighth transmembrane segment, causes
    near-complete de-glycosylation, mistargeting, and loss of proton-pumping
    activity of NHE1; truncating variants such as p.Ile288Serfs*9 also cause
    disease.
  genes:
  - preferred_term: SLC9A1
    term:
      id: hgnc:11071
      label: SLC9A1
  molecular_functions:
  - preferred_term: sodium:proton antiporter activity
    term:
      id: GO:0015385
      label: sodium:proton antiporter activity
    modifier: DECREASED
  evidence:
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identified the homozygous p.Gly305Arg missense mutation in SLC9A1 that segregates with the disease in a large consanguineous family"
    explanation: Identifies SLC9A1 as the disease gene with a homozygous missense mutation segregating in the affected family.
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We demonstrate that the p.Gly305Arg mutation causes the near complete de-glycosylation, mis-targeting and loss of proton pumping activity of NHE1."
    explanation: Functional assays demonstrate the variant abolishes NHE1 proton-pumping activity, establishing loss of function.
  - reference: PMID:30018422
    reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identified a novel homozygous SLC9A1 truncating mutation, c.862del (p.Ile288Serfs*9), in two affected siblings"
    explanation: Documents an additional biallelic truncating SLC9A1 variant causing the disorder, supporting a loss-of-function mechanism.
  downstream:
  - target: Impaired intracellular pH homeostasis
    causal_link_type: DIRECT
    description: Loss of NHE1 proton extrusion directly impairs regulation of intracellular pH.
- name: Impaired intracellular pH homeostasis
  description: >
    NHE1 maintains intracellular pH by exchanging one intracellular proton for
    one extracellular sodium ion. Loss of NHE1 function leads to dysregulated
    intracellular pH, which is especially deleterious in the central nervous
    system.
  biological_processes:
  - preferred_term: regulation of intracellular pH
    term:
      id: GO:0051453
      label: regulation of intracellular pH
    modifier: ABNORMAL
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:30018422
    reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NHE1 plays an important role in maintaining intracellular pH homeostasis by exchanging one intracellular proton for one extracellular sodium ion."
    explanation: Establishes the molecular role of NHE1 in intracellular pH homeostasis that is lost in this disease.
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the association between ataxia and hearing loss is caused by complete or near complete loss of function of NHE1 and altered regulation of pHi in the central nervous system"
    explanation: Links loss of NHE1 function and altered intracellular pH regulation in the CNS to the ataxia-deafness phenotype.
  downstream:
  - target: Selective neuronal vulnerability and neurodegeneration
    causal_link_type: DIRECT
    description: Dysregulated intracellular pH produces selective vulnerability and death of cerebellar neurons and cochlear hair cells.
- name: Selective neuronal vulnerability and neurodegeneration
  description: >
    Loss of NHE1-dependent pH regulation produces selective neuronal cell death.
    The cerebellum (including Purkinje cells) and the cochlea (sensory hair
    cells) are particularly vulnerable, producing progressive cerebellar ataxia
    and sensorineural hearing loss. The spontaneous and knockout Slc9a1 (Nhe1)
    mouse models recapitulate ataxia, recurrent seizures, and selective neuronal
    cell death.
  cell_types:
  - preferred_term: cerebellar Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  - preferred_term: cochlear hair cell
    term:
      id: CL:4023120
      label: cochlea auditory hair cell
  evidence:
  - reference: PMID:30018422
    reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mice with a homozygous null mutation in Slc9a1 (Nhe1) exhibited ataxia, recurrent seizures, and selective neuronal cell death."
    explanation: The Slc9a1-null mouse model demonstrates that NHE1 loss causes ataxia, seizures, and selective neuronal degeneration.
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The comparison of our family with the phenotypes of spontaneous and knockout Slc9a1 murine models"
    explanation: Phenotypic comparison with spontaneous and knockout Slc9a1 mouse models supports neurodegeneration as the mechanism linking the human phenotype to NHE1 loss.
  downstream:
  - target: Cerebellar ataxia
    causal_link_type: DIRECT
    description: Cerebellar neurodegeneration produces progressive cerebellar ataxia.
  - target: Sensorineural hearing impairment
    causal_link_type: DIRECT
    description: Cochlear hair cell vulnerability produces progressive sensorineural hearing loss.
  - target: Cerebellar atrophy
    causal_link_type: DIRECT
    description: Progressive cerebellar neuronal loss produces cerebellar atrophy on neuroimaging.
  - target: Dysarthria
    causal_link_type: DIRECT
    description: Cerebellar neurodegeneration can produce dysarthria as part of the progressive ataxia syndrome.
    evidence:
    - reference: PMID:25205112
      reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
      explanation: Dysarthria is linked here as a cerebellar sign within the documented ataxia syndrome.
  - target: Nystagmus
    causal_link_type: DIRECT
    description: Cerebellar neurodegeneration can produce nystagmus as an oculomotor sign of the ataxia syndrome.
    evidence:
    - reference: PMID:25205112
      reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
      explanation: Nystagmus is linked here as a cerebellar oculomotor sign within the documented ataxia syndrome.
  - target: Seizures
    causal_link_type: DIRECT
    description: Slc9a1/NHE1 loss can produce recurrent seizures in the NHE1-loss phenotype spectrum.
    evidence:
    - reference: PMID:30018422
      reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
      supports: PARTIAL
      evidence_source: MODEL_ORGANISM
      snippet: "Mice with a homozygous null mutation in Slc9a1 (Nhe1) exhibited ataxia, recurrent seizures, and selective neuronal cell death."
      explanation: The mouse model supports recurrent seizures as a downstream consequence of Slc9a1/NHE1 loss.
phenotypes:
- name: Cerebellar ataxia
  category: Neurologic
  description: >
    Progressive cerebellar ataxia is a defining feature, presenting in childhood
    or young adulthood with gait ataxia, action tremor, dysmetria, and
    dysdiadochokinesis.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
    explanation: Defines cerebellar ataxia as a core feature of the syndrome.
  - reference: PMID:30018422
    reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients showed cerebellar ataxia but neither of them showed sensorineural hearing loss nor a neuromuscular phenotype."
    explanation: A second family confirms cerebellar ataxia as a consistent feature of SLC9A1-related disease.
- name: Sensorineural hearing impairment
  category: Auditory
  description: >
    Severe progressive sensorineural hearing loss is a defining feature in the
    founding family, although it may be absent in some patients with SLC9A1
    variants.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
    explanation: Defines sensorineural hearing loss as a core feature of the syndrome.
  - reference: PMID:30018422
    reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "deafness may not be an essential phenotypic feature of SLC9A1 mutation"
    explanation: Notes that hearing loss, while characteristic, is variable and may be absent in some SLC9A1-mutated patients.
- name: Cerebellar atrophy
  category: Neurologic
  description: >
    Neuroimaging characteristically shows cerebellar atrophy consistent with the
    progressive cerebellar neurodegeneration.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:30018422
    reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "Mice with a homozygous null mutation in Slc9a1 (Nhe1) exhibited ataxia, recurrent seizures, and selective neuronal cell death."
    explanation: Selective cerebellar neuronal cell death in the Slc9a1-null mouse underlies the cerebellar atrophy seen in patients; direct human cerebellar atrophy is documented in the disease's clinical descriptions (MONDO/OMIM).
- name: Dysarthria
  category: Neurologic
  description: Cerebellar dysarthria accompanies the progressive cerebellar syndrome.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
    explanation: Dysarthria is a cerebellar sign within the ataxia syndrome described; this evidence supports the cerebellar syndrome of which dysarthria is a component.
- name: Nystagmus
  category: Neurologic
  description: Nystagmus is an oculomotor cerebellar sign reported in the syndrome.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
    explanation: Nystagmus is a cerebellar oculomotor sign within the ataxia syndrome described; this evidence supports the cerebellar syndrome of which nystagmus is a component.
- name: Seizures
  category: Neurologic
  description: >
    Seizures are part of the Slc9a1-null (slow-wave epilepsy, "swe") mouse
    phenotype and are reported in the broader SLC9A1-related disease spectrum.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:30018422
    reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "Mice with a homozygous null mutation in Slc9a1 (Nhe1) exhibited ataxia, recurrent seizures, and selective neuronal cell death."
    explanation: The Slc9a1-null mouse exhibits recurrent seizures, supporting seizures as part of the NHE1-loss phenotype spectrum; classified MODEL_ORGANISM as the quoted evidence is from mice.
genetic:
- name: SLC9A1 variants
  gene_term:
    preferred_term: SLC9A1
    term:
      id: hgnc:11071
      label: SLC9A1
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:25205112
      reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
      explanation: States autosomal recessive inheritance.
  variants:
  - name: p.Gly305Arg (c.913G>A)
    description: >
      Homozygous missense variant in the founding consanguineous family,
      affecting a highly conserved residue in the eighth transmembrane segment of
      NHE1; causes near-complete de-glycosylation, mistargeting, and loss of
      proton-pumping activity.
    evidence:
    - reference: PMID:25205112
      reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mutant glycine 305 is a highly conserved amino acid present in the eighth transmembrane segment of all metazoan orthologues of NHE1, the Na(+)/H(+) exchanger 1, encoded by SLC9A1."
      explanation: Documents the p.Gly305Arg variant and the conserved transmembrane residue it affects.
  - name: p.Ile288Serfs*9 (c.862del)
    description: >
      Homozygous truncating frameshift variant identified in two affected
      siblings with cerebellar ataxia without hearing loss, expanding the SLC9A1
      mutational and phenotypic spectrum.
    evidence:
    - reference: PMID:30018422
      reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "we identified a novel homozygous SLC9A1 truncating mutation, c.862del (p.Ile288Serfs*9), in two affected siblings"
      explanation: Documents a biallelic truncating variant supporting loss of function.
  features: >
    SLC9A1 encodes NHE1, the major plasma-membrane Na+/H+ exchanger. Biallelic
    loss-of-function variants (missense abolishing transport, or truncating
    frameshift) cause Lichtenstein-Knorr syndrome / SCAR19.
  evidence:
  - reference: PMID:30018422
    reference_title: "A novel SLC9A1 mutation causes cerebellar ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "c.913G>A (p.Gly305Arg), which caused Lichtenstein-Knorr syndrome characterized by cerebellar ataxia and sensorineural hearing loss"
    explanation: Confirms the SLC9A1 p.Gly305Arg genotype-phenotype relationship for Lichtenstein-Knorr syndrome.
treatments:
- name: Hearing Rehabilitation
  description: >
    Hearing aids and, for severe-to-profound sensorineural hearing loss,
    cochlear implantation are used to address the progressive deafness component.
  treatment_term:
    preferred_term: hearing aid usage
    term:
      id: MAXO:0009030
      label: hearing aid usage
  target_phenotypes:
  - preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
    explanation: The hearing-loss component supports auditory rehabilitation as supportive management; no disease-modifying therapy exists.
- name: Cochlear Implantation
  description: >
    Cochlear implantation is an option for severe-to-profound sensorineural
    hearing loss not adequately addressed by hearing aids.
  treatment_term:
    preferred_term: cochlear device implantation
    term:
      id: MAXO:0009025
      label: cochlear device implantation
  target_phenotypes:
  - preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
    explanation: The severe progressive sensorineural hearing loss supports cochlear implantation as a management option; this is supportive, not disease-modifying.
- name: Supportive and Rehabilitative Care
  description: >
    No disease-modifying therapy exists. Management is supportive, including
    physiotherapy and occupational therapy for ataxia, mobility aids, and
    seizure control where present.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:25205112
    reference_title: "Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Lichtenstein-Knorr syndrome is an autosomal recessive condition that associates sensorineural hearing loss and cerebellar ataxia."
    explanation: The progressive ataxia and associated neurologic features warrant supportive and rehabilitative care; no targeted treatment is established.

📚

References & Deep Research

Deep Research

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 36 citations 2026-06-04T18:29:52.932050

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Lichtenstein-Knorr Syndrome
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Lichtenstein-Knorr Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Lichtenstein–Knorr Syndrome (SNX14-related SCAR20)

Executive summary

Lichtenstein–Knorr syndrome is now commonly operationalized in the contemporary genetics literature as SNX14-related autosomal recessive spinocerebellar ataxia 20 (SCAR20; OMIM 616354), a childhood-onset syndromic neurodevelopmental/neurodegenerative disorder with progressive cerebellar atrophy/ataxia, severe global developmental delay/intellectual disability, absent or markedly impaired speech, and a distinctive coarse facial gestalt, variably accompanied by seizures, autism-like features, hearing loss, and skeletal anomalies. (thomas2015mutationsinsnx14 pages 1-3, akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4)

Preferred name	Synonyms/alternate names	OMIM disease number	Gene (HGNC symbol)	Inheritance	Key defining features (1 line)	Key references (with DOI/URL and year)
Lichtenstein-Knorr syndrome	Spinocerebellar ataxia, autosomal recessive 20; SCAR20; SNX14-related cerebellar ataxia and intellectual disability syndrome; distinctive autosomal-recessive cerebellar ataxia and intellectual disability syndrome (thomas2015mutationsinsnx14 pages 1-3, bryant2018snx14mutationsaffect pages 1-2, maia2020twocompoundheterozygous pages 1-2, levchenko2023homozygousdeepintronic pages 1-2)	OMIM 616354 (maia2020twocompoundheterozygous pages 1-2, levchenko2023homozygousdeepintronic pages 1-2, shao2024compoundheterozygousmutation pages 1-2)	SNX14 (HGNC symbol: SNX14) (thomas2015mutationsinsnx14 pages 1-3, shao2024compoundheterozygousmutation pages 1-2)	Autosomal recessive (thomas2015mutationsinsnx14 pages 1-3, bryant2018snx14mutationsaffect pages 1-2, shao2024compoundheterozygousmutation pages 1-2)	Early-onset progressive cerebellar ataxia/atrophy with severe intellectual disability or developmental delay, absent or markedly impaired speech, relative macrocephaly, coarse facial features, and frequent additional findings such as hypotonia, hearing loss, skeletal anomalies, autism, or seizures (thomas2015mutationsinsnx14 pages 1-3, bryant2018snx14mutationsaffect pages 1-2, maia2020twocompoundheterozygous pages 1-2, levchenko2023homozygousdeepintronic pages 1-2, shao2024compoundheterozygousmutation pages 1-2)	Thomas et al., 2014, AJHG, doi:10.1016/j.ajhg.2014.10.007, https://doi.org/10.1016/j.ajhg.2015.05.010 (reported in retrieved source) (thomas2015mutationsinsnx14 pages 1-3); Bryant et al., 2018, Hum Mol Genet, doi:10.1093/hmg/ddy101, https://doi.org/10.1093/hmg/ddy101 (bryant2018snx14mutationsaffect pages 1-2); Maia et al., 2020, Front Genet, doi:10.3389/fgene.2020.01038, https://doi.org/10.3389/fgene.2020.01038 (maia2020twocompoundheterozygous pages 1-2); Levchenko et al., 2023, Front Genet, doi:10.3389/fgene.2023.1197681, https://doi.org/10.3389/fgene.2023.1197681 (levchenko2023homozygousdeepintronic pages 1-2); Shao et al., 2024, Front Genet, doi:10.3389/fgene.2024.1379366, https://doi.org/10.3389/fgene.2024.1379366 (shao2024compoundheterozygousmutation pages 1-2)
MONDO / MeSH / ICD identifiers	not found in retrieved sources (levchenko2023homozygousdeepintronic pages 1-2, thomas2015mutationsinsnx14 pages 1-3)	not found in retrieved sources (levchenko2023homozygousdeepintronic pages 1-2, thomas2015mutationsinsnx14 pages 1-3)	not applicable	not applicable	Cross-ontology identifiers beyond OMIM were not reported in the retrieved evidence set (levchenko2023homozygousdeepintronic pages 1-2, thomas2015mutationsinsnx14 pages 1-3)	Evidence base searched here did not yield MONDO, MeSH, ICD-10, or ICD-11 identifiers in retrieved sources (levchenko2023homozygousdeepintronic pages 1-2, thomas2015mutationsinsnx14 pages 1-3)

Table: This table summarizes the main disease names, aliases, OMIM identifier, causal gene, inheritance, and defining clinical features for Lichtenstein-Knorr syndrome / SNX14-related SCAR20. It is useful as a compact reference for disease knowledge-base normalization and synonym mapping.

1. Disease information

1.1 Definition and current understanding

Foundational case series established biallelic SNX14 loss-of-function as the cause of a distinctive, recognizable recessive syndrome with combined cerebellar atrophy/ataxia and severe neurodevelopmental impairment. (thomas2015mutationsinsnx14 pages 1-3, akizu2015biallelicmutationsin pages 21-23)

Direct abstract quote (foundational genetics): Akizu et al. (Nature Genetics, Apr 2015) state: “Pediatric-onset ataxias often present clinically as developmental delay and intellectual disability, with prominent cerebellar atrophy as a key neuroradiographic finding. Here we describe a new clinically distinguishable recessive syndrome in 12 families with cerebellar atrophy together with ataxia, coarsened facial features and intellectual disability, due to truncating mutations in the sorting nexin gene SNX14 …” and “Our results characterize a unique ataxia syndrome due to biallelic SNX14 mutations leading to lysosome-autophagosome dysfunction.” (https://doi.org/10.1038/ng.3256; publication date Apr 2015). (akizu2015biallelicmutationsin pages 1-3)

1.2 Key identifiers and nomenclature

OMIM disease: SCAR20 / Spinocerebellar ataxia, autosomal recessive 20: OMIM 616354. (levchenko2023homozygousdeepintronic pages 1-2, maia2020twocompoundheterozygous pages 1-2)
Gene: SNX14 (Sorting nexin 14). (thomas2015mutationsinsnx14 pages 1-3)
Synonyms in retrieved sources: “SCAR20,” “autosomal recessive spinocerebellar ataxia 20,” “distinctive autosomal-recessive cerebellar ataxia and intellectual disability syndrome,” and “SNX14-related cerebellar ataxia and intellectual disability syndrome.” (thomas2015mutationsinsnx14 pages 1-3, bryant2018snx14mutationsaffect pages 1-2, levchenko2023homozygousdeepintronic pages 1-2)
PMID: The Thomas et al. AJHG report is referenced with PMID: 25439728 in the retrieved evidence set. (akizu2015biallelicmutationsin pages 11-13)

Not found in retrieved sources: MONDO, MeSH, ICD-10/ICD-11 codes (not captured in the retrieved texts for this run). (levchenko2023homozygousdeepintronic pages 1-2, thomas2015mutationsinsnx14 pages 1-3)

1.3 Evidence source type

The disease characterization here is derived primarily from: * Aggregated cohorts (e.g., 22-individual cohort tables; multi-family ascertainment) (akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4) * Human case reports and small family series (e.g., deep intronic variant requiring WGS; compound-heterozygous families) (levchenko2023homozygousdeepintronic pages 1-2, shao2024compoundheterozygousmutation pages 1-2) * Model organism studies (mouse, zebrafish; plus canine naturally occurring disease) (zhang2021snx14deficiencyinduceddefective pages 1-2, akizu2015biallelicmutationsin pages 21-23, bryant2018snx14mutationsaffect pages 1-2)

2. Etiology

2.1 Primary causal factors

Genetic etiology (Mendelian): biallelic pathogenic variants in SNX14 cause the disorder, typically via loss-of-function (nonsense/frameshift/splice, deletions/rearrangements, and deep intronic pseudo-exon activation). (thomas2015mutationsinsnx14 pages 3-5, akizu2015biallelicmutationsin pages 3-4, levchenko2023homozygousdeepintronic pages 1-2)

2.2 Risk factors

Family history consistent with autosomal recessive inheritance; many families are consanguineous in initial cohorts. (thomas2015mutationsinsnx14 pages 3-5, akizu2015biallelicmutationsin pages 3-4)
Founder effect: In a 96-family childhood-onset recessive cerebellar atrophy cohort, three families shared SNX14 p.Arg378* on a shared haplotype, consistent with a founder allele. (akizu2015biallelicmutationsin pages 3-4)

2.3 Protective factors / gene–environment interactions

No protective genetic or environmental factors and no gene–environment interaction data were identified in the retrieved sources for this run.

3. Phenotypes

3.1 Core phenotype spectrum (with frequencies where available)

A high-penetrance, syndromic phenotype is supported by cohort-level data.

Akizu et al. cohort (n=22): universal global developmental impairment (delayed gross motor, fine motor, language, and social development 22/22), hypotonia 22/22, wide-based or absent gait 22/22, cerebellar atrophy on MRI 22/22, and coarse facies 22/22; common additional features include autistic-like behavior 12/22, seizures 8/22, nystagmus 11/22, and hearing loss 5/22. (akizu2015biallelicmutationsin pages 21-23)

Thomas et al. cohort (n=7): severe neurodevelopmental disability with absent/severely impaired speech (5/7), hypotonia (6/7), progressive cerebellar atrophy (5/7), pontine thinning (4/7), and sensorineural hearing loss (5/7), plus consistent coarse craniofacial gestalt and digital anomalies (e.g., 5th-finger brachy/camptodactyly 6/7). (thomas2015mutationsinsnx14 pages 3-5)

3.2 Onset and progression

Typical presentation occurs between birth and 1 year with global developmental delay and hypotonia; cerebellar atrophy is described as age-dependent (can be absent in early infancy and become progressive). (akizu2015biallelicmutationsin pages 3-4, kim2021twokoreansiblings pages 3-4)

3.3 Quality-of-life / functional impact

Cohort language indicates profound functional impact on core domains: * Mobility: “wide-based or absent gait” (Akizu cohort) and only a minority achieving even assisted walking in the Thomas cohort, with only one individual reaching independent ambulation in that series. (akizu2015biallelicmutationsin pages 21-23, thomas2015mutationsinsnx14 pages 3-5) * Communication: “delayed or absent language” in Akizu cohort and frequent absent/severely impaired speech in Thomas cohort. (akizu2015biallelicmutationsin pages 21-23, thomas2015mutationsinsnx14 pages 3-5)

3.4 Suggested HPO terms

A curated phenotype-to-HPO mapping with cohort frequencies is provided in the artifact below.

Phenotype	HPO term(s)	Frequency (Akizu 2015)	Frequency (Thomas 2014)	Onset/progression notes	Evidence citations
Global developmental delay / severe developmental impairment	HP:0001263 Developmental delay; HP:0011344 Severe global developmental delay	22/22 delayed gross motor; 22/22 delayed fine motor; 22/22 delayed/absent social development	Severe intellectual disability in most; 7/7 affected with major neurodevelopmental impairment	Usually presents between birth and 1 year; early pervasive developmental impairment	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5)
Intellectual disability	HP:0001249 Intellectual disability; HP:0010864 Severe intellectual disability	Not separately enumerated in retrieved Akizu table text, but syndrome includes intellectual disability across cohort	Severe in most; 1 moderate among 7	Early-onset, persistent cognitive disability	(akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5, akizu2015biallelicmutationsin pages 1-3)
Speech delay / absent speech	HP:0000750 Delayed speech and language development; HP:0001344 Absent speech	22/22 delayed or absent language	5/7 absent or severely impaired speech	Major communication impairment from infancy/early childhood; often lifelong	(akizu2015biallelicmutationsin pages 21-23, thomas2015mutationsinsnx14 pages 3-5, kim2021twokoreansiblings pages 3-4)
Hypotonia	HP:0001252 Hypotonia	22/22	6/7	Present from infancy; often among earliest signs	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5)
Ataxia / gait abnormality / absent ambulation	HP:0001251 Ataxia; HP:0002066 Gait ataxia; HP:0002540 Inability to walk	22/22 wide-based gait or absent gait	Ataxia in 5/6 assessed; only 1/7 achieved independent ambulation by age 3 years	Early motor delay; ambulation often absent or markedly delayed; cerebellar signs progressive	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5)
Delayed motor milestones	HP:0001270 Motor delay; HP:0002194 Delayed gross motor development	22/22 gross motor delay	Sitting markedly delayed; only 4/7 walked with help	Childhood-onset; substantial impact on mobility and daily function	(akizu2015biallelicmutationsin pages 21-23, thomas2015mutationsinsnx14 pages 3-5, kim2021twokoreansiblings pages 3-4)
Cerebellar atrophy	HP:0001272 Cerebellar atrophy	22/22	5/7	Age-dependent; may be absent in infancy/early imaging and then become progressive	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5, kim2021twokoreansiblings pages 3-4)
Pontine thinning	HP:0001302 Pontocerebellar hypoplasia / HP:0006829 Pontine atrophy (closest related HPO concepts)	Not specified in retrieved Akizu frequency text	4/7	Reported on MRI in Thomas cohort; brainstem relatively preserved compared with cerebellum in some images	(thomas2015mutationsinsnx14 pages 3-5, thomas2015mutationsinsnx14 media ca718e7a)
Coarse facial features	HP:0000280 Coarse facial features	22/22	7/7	Distinctive gestalt supports recognition; features may become progressively coarse	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5)
Relative macrocephaly / macrocephaly	HP:0000256 Macrocephaly; HP:0011227 Relative macrocephaly	Not quantified in retrieved Akizu table text	Several individuals had OFC >97th centile; not summarized as total count in retrieved text	Relative macrocephaly noted as characteristic syndrome feature	(akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5)
Hearing loss (sensorineural)	HP:0000407 Sensorineural hearing impairment	5/22	5/7	Variable associated feature; not universal	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5)
Seizures / epilepsy	HP:0001250 Seizure	8/22; about half developed seizures by age 2 years in narrative summary	Absent in original Thomas family set per syndrome description	Variable; often early childhood onset when present; reported as medically controllable in Akizu series	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 1-3)
Nystagmus / oculomotor abnormality	HP:0000639 Nystagmus	11/22	Not reported as frequency in Thomas retrieved table text	Common associated neurologic sign in Akizu cohort	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 3-4)
Autism-like / stereotyped behavior	HP:0000729 Autistic behavior; HP:0000733 Stereotypy	12/22 autistic-like behavior	Not reported in Thomas table	Neurobehavioral manifestation in a substantial subset	(akizu2015biallelicmutationsin pages 21-23)
Hyporeflexia / areflexia	HP:0001265 Hyporeflexia; HP:0001284 Areflexia	Reduced deep tendon reflexes in most children (narrative)	5/6 hypo/areflexia	Peripheral neurologic involvement accompanies cerebellar syndrome	(akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5)
Fifth-finger brachy/camptodactyly / broad short digits	HP:0004209 Camptodactyly of finger; HP:0001182 Brachydactyly; HP:0009381 Broad finger	Kyphoscoliosis/clinodactyly 10/22	6/7 brachy/camptodactyly of 5th fingers; 7/7 short broad fingers/toes	Skeletal/digital anomalies are common supportive findings	(akizu2015biallelicmutationsin pages 21-23, thomas2015mutationsinsnx14 pages 3-5)
Hypertrichosis	HP:0000998 Hypertrichosis	12/22	Not reported in Thomas table	Variable syndromic feature	(akizu2015biallelicmutationsin pages 21-23)
Macroglossia	HP:0000158 Macroglossia	12/22	Not reported in Thomas table	Variable syndromic feature	(akizu2015biallelicmutationsin pages 21-23)
Hepatosplenomegaly	HP:0001433 Hepatosplenomegaly	5/22	Not reported in Thomas table	Infrequent extra-neurologic feature; helped raise lysosomal-storage-disease differential in some cases	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 4-6)
Abnormal urine oligosaccharides / glycosaminoglycans	HP:0033106 Abnormal urine oligosaccharide level; HP:0012411 Abnormal urinary glycosaminoglycan excretion	5/22 abnormal oligosaccharides or GAG-related testing in retrieved table summary	Not reported	Laboratory abnormalities were inconsistent and lysosomal enzyme assays could be unrevealing	(akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 4-6)

Table: This table maps core phenotypes of SNX14-related SCAR20/Lichtenstein-Knorr syndrome to suggested HPO terms and summarizes frequencies from the Akizu 2015 and Thomas 2014 cohorts where available. It is useful for phenotype curation, ontology annotation, and comparing syndrome-defining features across the two foundational cohorts.

4. Genetic / molecular information

4.1 Causal gene and inheritance

Causal gene: SNX14. (thomas2015mutationsinsnx14 pages 1-3)
Inheritance: autosomal recessive. (thomas2015mutationsinsnx14 pages 1-3, akizu2015biallelicmutationsin pages 3-4)

4.2 Pathogenic variant classes and examples

Across cohorts and recent case reports, reported pathogenic mechanisms include: * Truncating and splice loss-of-function variants (common in early cohorts). (akizu2015biallelicmutationsin pages 3-4, thomas2015mutationsinsnx14 pages 3-5) * Large deletions and complex rearrangements that evade standard SNV-only pipelines. (maia2020twocompoundheterozygous pages 1-2) * Deep intronic splice-altering variants detected by WGS (pseudo-exon activation; premature stop). (levchenko2023homozygousdeepintronic pages 1-2) * Compound heterozygosity increasingly reported (e.g., nonsense + rearrangement; nonsense + missense VUS with functional effect on expression). (maia2020twocompoundheterozygous pages 1-2, shao2024compoundheterozygousmutation pages 1-2)

Example population frequency: SNX14 c.2746-2A>G reported with gnomAD allele frequency 1/245460. (kim2021twokoreansiblings pages 3-4)

A structured, curation-ready variant summary is provided below.

Publication (year)	PMID	Family structure / consanguinity	Variant(s) (HGVS c. and p.)	Variant type	Zygosity	ACMG classification	Key genotype-phenotype notes (1 line)	Notable population data
Thomas et al. (2014/2015)	25439728	3 unrelated consanguineous families; 7 affected individuals total (5F, 2M) (akizu2015biallelicmutationsin pages 11-13, thomas2015mutationsinsnx14 pages 3-5)	Family 1: c.2596C>T, p.Gln866*; Family 2: c.1108+1181_2108-2342del, p.Val369_Leu702del; Family 3: c.1894+1G>A, splice effect reported as p.Ala603_Gly632del / part-PX-domain deletion in retrieved text (thomas2015mutationsinsnx14 pages 3-5)	Nonsense; multiexon deletion; splice-site (thomas2015mutationsinsnx14 pages 3-5)	Homozygous in each family (thomas2015mutationsinsnx14 pages 3-5)	Not stated in retrieved text	Severe intellectual disability, hypotonia, delayed milestones, ataxia, progressive cerebellar atrophy (5/7), pontine thinning (4/7), hearing loss (5/7); mutations predicted to disrupt/remove PX and/or RGS domains (thomas2015mutationsinsnx14 pages 3-5)	Not stated in retrieved text
Akizu et al. (2015)	not in retrieved text	Initial cohort of 96 families with childhood-onset recessive cerebellar atrophy; 81 consanguineous families; identified 16 patients from 8 families with truncating SNX14 variants; later summary table covered 22 affected individuals from 12 families (akizu2015biallelicmutationsin pages 3-4, akizu2015biallelicmutationsin pages 21-23, akizu2015biallelicmutationsin pages 1-3)	Specific family-level HGVS not fully enumerated in retrieved text; study summary reports truncating / loss-of-function biallelic SNX14 variants including recurrent founder p.Arg378* allele in 3 families (akizu2015biallelicmutationsin pages 3-4)	Truncating loss-of-function variants (nonsense/frameshift/splice not individually resolved in retrieved text) (akizu2015biallelicmutationsin pages 3-4, akizu2015biallelicmutationsin pages 1-3)	Biallelic; predominantly homozygous in consanguineous families (akizu2015biallelicmutationsin pages 3-4)	Not stated in retrieved text	Distinct syndromic cerebellar atrophy with coarse facies in all, onset birth-1 year, hypotonia, seizures in ~50% by age 2, hearing loss in ~1/3; patient cells showed engorged lysosomes and slower autophagosome clearance (akizu2015biallelicmutationsin pages 3-4, akizu2015biallelicmutationsin pages 13-21, akizu2015biallelicmutationsin pages 21-23)	Founder allele p.Arg378* on a 1.5 Mb haplotype in 3 families; SNX14 accounted for ~10% of families in this cohort (akizu2015biallelicmutationsin pages 3-4)
Maia et al. (2020)	not in retrieved text	First reported non-consanguineous SCAR20 family; 2 affected siblings (maia2020twocompoundheterozygous pages 1-2)	c.1195C>T, p.Arg399* plus complex rearrangement c.[612+3028_698-2759del;698-2758_698-516inv;698-515_1171+1366delinsAG] (maia2020twocompoundheterozygous pages 1-2)	Nonsense + complex genomic rearrangement (2 deletions, inversion, insertion) (maia2020twocompoundheterozygous pages 1-2)	Compound heterozygous (maia2020twocompoundheterozygous pages 1-2)	Not stated in retrieved text	Extended phenotype with dystonia and stereotypies in addition to classic SCAR20 features; MRI showed diffuse cerebellar and pontine atrophy (maia2020twocompoundheterozygous pages 1-2)	Not stated in retrieved text
Kim et al. (2021)	not in retrieved text	Korean family with 2 affected siblings; parents heterozygous carriers; report notes prior cases mostly from consanguineous families (kim2021twokoreansiblings pages 3-4, kim2021twokoreansiblings pages 1-3)	c.2746-2A>G (splice acceptor) (kim2021twokoreansiblings pages 3-4, kim2021twokoreansiblings pages 1-3)	Splice-site loss-of-function (kim2021twokoreansiblings pages 3-4, kim2021twokoreansiblings pages 1-3)	Homozygous in both siblings (kim2021twokoreansiblings pages 3-4, kim2021twokoreansiblings pages 1-3)	Pathogenic (reported in summary of retrieved evidence) (kim2021twokoreansiblings pages 3-4)	Severe developmental delay with progressive cerebellar atrophy in older sibling; younger sibling had initially intact cerebellum, illustrating age-dependent imaging progression (kim2021twokoreansiblings pages 3-4, kim2021twokoreansiblings pages 1-3)	gnomAD allele frequency reported as 1/245460 for c.2746-2A>G (kim2021twokoreansiblings pages 3-4)
Levchenko et al. (2023)	not in retrieved text	2 sisters from a consanguineous family (levchenko2023homozygousdeepintronic pages 1-2)	c.462-589A>G causing pseudo-exon inclusion; protein consequence p.Asp155Valfs*8 (levchenko2023homozygousdeepintronic pages 1-2)	Deep intronic splice-altering variant causing frameshift / premature stop (levchenko2023homozygousdeepintronic pages 1-2)	Homozygous (levchenko2023homozygousdeepintronic pages 1-2)	Not stated in retrieved text	First deep intronic SNX14 case; diagnosis required trio WGS after extensive diagnostic workup and expanded SCAR20 mutational spectrum beyond coding/canonical splice variants (levchenko2023homozygousdeepintronic pages 1-2)	Retrieved text notes 28 pathogenic/likely pathogenic SNX14 variants in ClinVar and >36 patients from 19 families, but no variant-specific population AF (levchenko2023homozygousdeepintronic pages 1-2)
Shao et al. (2024)	not in retrieved text	Family with 2 affected children (siblings) and unaffected carrier parents; prenatal ultrasound abnormalities prompted evaluation (shao2024compoundheterozygousmutation pages 1-2)	c.712A>T, p.Arg238Ter and c.2744A>T, p.Gln915Leu (shao2024compoundheterozygousmutation pages 1-2)	Nonsense + missense (shao2024compoundheterozygousmutation pages 1-2)	Compound heterozygous (shao2024compoundheterozygousmutation pages 1-2)	p.Arg238Ter: pathogenic; p.Gln915Leu: VUS (ACMG, as stated) (shao2024compoundheterozygousmutation pages 1-2)	In vitro experiments showed both variants reduced SNX14 expression; phenotype included prenatal skeletal/craniofacial abnormalities, postnatal developmental delay and hypotonia (shao2024compoundheterozygousmutation pages 1-2)	Not stated in retrieved text

Table: This table summarizes reported SNX14 disease-causing variants and key genetic evidence for Lichtenstein-Knorr syndrome/SCAR20 from the retrieved literature. It highlights variant class, zygosity, family structure, and notable genotype-phenotype or population observations useful for curation.

4.3 Functional consequence (current consensus)

Most disease-associated alleles are interpreted as producing loss of normal SNX14 function, either by truncation, splicing disruption, deletion/rearrangement, or markedly reduced expression. (akizu2015biallelicmutationsin pages 3-4, levchenko2023homozygousdeepintronic pages 1-2, shao2024compoundheterozygousmutation pages 1-2)

4.4 Modifier genes / epigenetics

No validated modifier genes or disease-specific epigenetic signatures were identified in the retrieved sources for this run.

5. Environmental information

No established non-genetic causal or modifying environmental factors were identified in the retrieved sources for this run.

6. Mechanism / pathophysiology

SNX14-related disease has converging evidence for a multi-step mechanism linking organelle homeostasis defects to selective Purkinje cell vulnerability.

6.1 Lysosome–autophagosome dysfunction (human cells and zebrafish)

Akizu et al. report SNX14 localization to lysosomal compartments and cellular evidence of engorged lysosomes and slower autophagosome clearance upon starvation, with zebrafish knockdown showing cerebellar tissue loss and autophagosome accumulation. (akizu2015biallelicmutationsin pages 1-3, akizu2015biallelicmutationsin pages 13-21, akizu2015biallelicmutationsin pages 21-23)

Dataset: WES data deposition noted at dbGaP phs000288. (akizu2015biallelicmutationsin pages 1-3)

6.2 ER–lipid droplet contact biology and lipid homeostasis (cell biology)

Mechanistic studies place SNX14 at the intersection of ER and lipid droplet (LD) biology: * SNX14 is described as an ER-localized/anchored protein implicated in ER-associated neutral lipid metabolism and lipid droplet association. (bryant2018snx14mutationsaffect pages 1-2, bryant2018snx14mutationsaffect pages 10-10) * Proximity labeling work indicates SNX14 promotes LD biogenesis during fatty acid flux and functionally interacts with the fatty acid desaturase SCD1; SCD1 overexpression rescues specific lipotoxic phenotypes. (datta2020snx14proximitylabeling pages 1-2)

6.3 Selective cerebellar vulnerability and lipidomic signatures (2024 JCI Insight)

Direct abstract quote (recent 2024 primary research): Zhou et al. (JCI Insight; accepted Apr 5, 2024; published Apr 16, 2024; https://doi.org/10.1172/jci.insight.168594) report: “Here, we show that cerebellar neurodegeneration caused by Sorting Nexin 14 (SNX14) deficiency is associated with lipid homeostasis defects …” and “predegenerating SNX14-deficient cerebella show a unique accumulation of acylcarnitines and depletion of triglycerides …” while “cerebellar Purkinje cells (PCs) are selectively vulnerable to SNX14 deficiency while forebrain regions preserve their neuronal content.” (zhou2024alteredlipidhomeostasis pages 1-2)

Dataset: RNA-seq deposited at GEO GSE215834. (zhou2024alteredlipidhomeostasis pages 17-18)

6.4 Axonal microtubule organization and mitochondrial transport; pharmacologic rescue (2021 mouse models)

Direct abstract quote (therapeutic-direction mechanistic model): Zhang et al. (National Science Review; advance access 10 Feb 2021; https://doi.org/10.1093/nsr/nwab024) report that SNX14 deficiency “disrupted microtubule organization and mitochondrial transport in axons” and that “The antiepileptic drug valproate ameliorated motor deficits and cerebellar degeneration in Snx14-deficient mice via the restoration of mitochondrial transport and function in Purkinje cells.” (zhang2021snx14deficiencyinduceddefective pages 1-2)

6.5 Causal chain (integrated view)

A synthesis consistent with the retrieved primary data is: 1) Biallelic SNX14 loss-of-function → 2) disturbed lysosome–autophagy and/or ER–LD lipid handling (cholesterol/neutral lipid imbalance; saturated FA lipotoxicity) → 3) tissue-specific lipid dysregulation (e.g., cerebellar acylcarnitine accumulation and triglyceride depletion) and organelle stress (lysosome enlargement, ER enlargement) → 4) disruption of axonal processes (microtubule/mitochondrial transport) and impaired energetic homeostasis → 5) selective Purkinje cell degeneration → 6) progressive cerebellar atrophy and clinical ataxia with severe neurodevelopmental disability. (akizu2015biallelicmutationsin pages 13-21, datta2020snx14proximitylabeling pages 1-2, zhou2024alteredlipidhomeostasis pages 1-2, zhang2021snx14deficiencyinduceddefective pages 1-2)

6.6 Ontology suggestions (mechanism annotation)

GO biological process (suggested): autophagy (GO:0006914), lysosome organization (GO:0007040), lipid droplet organization (GO:0034389), fatty acid metabolic process (GO:0006631), mitochondrial transport (GO:0006839 / related transport terms), microtubule cytoskeleton organization (GO:0000226). (akizu2015biallelicmutationsin pages 13-21, datta2020snx14proximitylabeling pages 1-2, zhang2021snx14deficiencyinduceddefective pages 1-2, zhou2024alteredlipidhomeostasis pages 1-2)
Cell Ontology (suggested): Purkinje cell (CL:0000121). (zhou2024alteredlipidhomeostasis pages 1-2, zhang2021snx14deficiencyinduceddefective pages 1-2)

7. Anatomical structures affected

7.1 Primary organs/systems

Central nervous system, with emphasis on cerebellum and Purkinje cells. (zhou2024alteredlipidhomeostasis pages 1-2, zhang2021snx14deficiencyinduceddefective pages 1-2)

7.2 Neuroimaging corroboration (with figure evidence)

MRI evidence in the Thomas cohort shows evolution from normal early imaging to later global cerebellar atrophy with thin folia and enlarged fissures, supporting age-dependent progression. (thomas2015mutationsinsnx14 media ca718e7a)

8. Temporal development (natural history)

8.1 Onset

Most patients present in infancy (birth–1 year) with global developmental delay and hypotonia. (akizu2015biallelicmutationsin pages 3-4)

8.2 Progression

Progressive cerebellar atrophy is documented in multiple cohorts and can be absent in very early imaging. (akizu2015biallelicmutationsin pages 3-4, kim2021twokoreansiblings pages 3-4)

Evidence gap: This run did not retrieve a longitudinal natural history study reporting survival, standardized ataxia scales over time, or life expectancy.

9. Inheritance and population

9.1 Epidemiology

In autosomal recessive cerebellar ataxia broadly, incidence/prevalence is cited as ~3 per 100,000 in a mechanistic mouse-model paper. (zhang2021snx14deficiencyinduceddefective pages 1-2)

SCAR20-specific prevalence/incidence was not provided in the retrieved sources.

9.2 Consanguinity and founder effects

In a 96-family cohort with childhood-onset recessive cerebellar atrophy, parental consanguinity was common and SNX14 explained ~10% of families; a p.Arg378* founder haplotype was observed in three families. (akizu2015biallelicmutationsin pages 3-4)

10. Diagnostics

10.1 Clinical suspicion and imaging

Key clinical clues supporting targeted genetic testing include: severe developmental delay with absent speech, hypotonia, progressive ataxia, coarse facies, and cerebellar atrophy (which may be absent early). (kim2021twokoreansiblings pages 3-4, akizu2015biallelicmutationsin pages 3-4)

Imaging features reported across series include progressive cerebellar atrophy and, in some cases, pontine thinning. (thomas2015mutationsinsnx14 pages 3-5)

10.2 Genetic testing strategy and real-world implementation

Whole-exome sequencing (WES) is the dominant diagnostic tool in published cases and cohorts; families are often diagnosed via WES with Sanger confirmation. (thomas2015mutationsinsnx14 pages 3-5, kim2021twokoreansiblings pages 1-3, shao2024compoundheterozygousmutation pages 1-2)

Whole-genome sequencing (WGS) is important in unsolved cases, particularly to detect: * deep intronic splice-altering variants (e.g., pseudo-exon activation) (levchenko2023homozygousdeepintronic pages 1-2) * complex rearrangements requiring qPCR/long-range PCR and breakpoint mapping beyond WES SNV calls. (maia2020twocompoundheterozygous pages 1-2)

A 2023 report emphasizes that WES yields can exceed panels in recessive ataxia evaluation and underscores WGS value for intronic/splicing variants. (levchenko2023homozygousdeepintronic pages 1-2)

10.3 Differential diagnosis considerations

Akizu et al. highlight resemblance to lysosomal storage disorders (storage-like coarse facies; organomegaly in a subset) and used exclusion criteria for multiple alternative etiologies during cohort assembly (e.g., other ataxias, white matter disease, lysosomal disorders). (akizu2015biallelicmutationsin pages 3-4, akizu2015biallelicmutationsin pages 6-8)

11. Outcome / prognosis

Robust survival and life-expectancy statistics were not present in the retrieved evidence set for this run. Available evidence supports a severe, childhood-onset disorder with persistent severe disability and progressive cerebellar degeneration in many individuals. (akizu2015biallelicmutationsin pages 3-4, zhou2024alteredlipidhomeostasis pages 1-2)

12. Treatment

12.1 Current standard of care (evidence in retrieved sources)

Evidence in retrieved sources primarily supports supportive/symptomatic management: * Seizure management: seizures “well controlled with anticonvulsant medication” in about half of affected children with seizures by age 2 in one cohort. (akizu2015biallelicmutationsin pages 3-4)

12.2 Experimental / emerging therapy signals

Valproate (preclinical): Valproate improved motor deficits and cerebellar degeneration in Snx14-deficient mice by restoring mitochondrial transport/function in Purkinje cells. (zhang2021snx14deficiencyinduceddefective pages 1-2)

Caution: This is preclinical mouse evidence; the retrieved evidence set did not include human clinical trials of valproate in SCAR20.

12.3 Suggested MAXO terms (management annotation; suggested)

Seizure management / antiepileptic therapy: MAXO:0000747 (anticonvulsant therapy; suggested mapping). (Supported generally by seizure control mention) (akizu2015biallelicmutationsin pages 3-4)
Rehabilitation therapy: physical therapy/occupational therapy (suggested; not specifically evaluated in retrieved texts).

13. Prevention

No disease-specific primary prevention is established. Practical prevention in an autosomal recessive disorder is genetic counseling, cascade testing, and reproductive options; these were not explicitly detailed in the retrieved sources but are implied by autosomal recessive inheritance and family-based diagnoses. (akizu2015biallelicmutationsin pages 3-4)

14. Other species / natural disease

A naturally occurring canine disorder in the Hungarian Vizsla associated with an SNX14 splice donor variant is cited as producing progressive ataxia and Purkinje degeneration, supporting cross-species relevance of SNX14 in cerebellar integrity. (bryant2018snx14mutationsaffect pages 1-2, kim2021twokoreansiblings pages 4-5)

15. Model organisms

15.1 Zebrafish

Zebrafish snx14 knockdown recapitulates key disease-relevant features including cerebellar/hindbrain pathology, autophagosome accumulation, and apoptosis, with rescue by human SNX14 mRNA in reported experiments. (akizu2015biallelicmutationsin pages 21-23)

15.2 Mouse

Two complementary mouse-model lines are represented in retrieved evidence: * CNS-restricted Snx14 deficiency causing Purkinje degeneration and motor deficits, mechanistically linked to microtubule disruption and mitochondrial transport defects; valproate rescue demonstrated. (zhang2021snx14deficiencyinduceddefective pages 1-2) * A full-body Snx14 KO model surviving to adulthood and recapitulating cerebellar and cognitive features, with selective Purkinje vulnerability and lipidomic signatures. (zhou2024alteredlipidhomeostasis pages 1-2)

15.3 Comparative mechanism conservation

Across species and model systems, SNX14 function converges on organelle homeostasis (lysosome/autophagy and ER–LD lipid handling) and Purkinje cell vulnerability. (akizu2015biallelicmutationsin pages 13-21, datta2020snx14proximitylabeling pages 1-2, zhou2024alteredlipidhomeostasis pages 1-2)

Recent developments (prioritizing 2023–2024)

1) Deep intronic variant discovery via WGS expands the mutational spectrum and reinforces WGS use when WES is negative (Frontiers in Genetics, Jul 2023; https://doi.org/10.3389/fgene.2023.1197681). (levchenko2023homozygousdeepintronic pages 1-2) 2) Mouse model + multi-omics link to lipid homeostasis defects and selective Purkinje vulnerability (JCI Insight, published Apr 16, 2024; https://doi.org/10.1172/jci.insight.168594; GEO GSE215834). (zhou2024alteredlipidhomeostasis pages 1-2, zhou2024alteredlipidhomeostasis pages 17-18) 3) New compound heterozygous family reports with functional validation (Frontiers in Genetics, Apr 2024; https://doi.org/10.3389/fgene.2024.1379366) emphasize variant interpretation under ACMG and in vitro expression consequences. (shao2024compoundheterozygousmutation pages 1-2)

Limitations of this report (due to retrieved-source constraints)

Cross-ontology identifiers (MONDO/MeSH/ICD) were not captured in the retrieved evidence set.
No SCAR20-specific prevalence/incidence, survival curves, or formal longitudinal natural-history metrics were retrieved.
Human interventional trial evidence (including valproate in patients) was not retrieved; valproate support here is preclinical.

Key primary references (URLs; dates)

Akizu et al. Nature Genetics. “Biallelic mutations in SNX14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction.” Apr 2015. https://doi.org/10.1038/ng.3256 (akizu2015biallelicmutationsin pages 1-3)
Thomas et al. American Journal of Human Genetics. “Mutations in SNX14 Cause a Distinctive Autosomal-Recessive Cerebellar Ataxia and Intellectual Disability Syndrome.” (PMID 25439728; table/figure evidence in retrieved text). (akizu2015biallelicmutationsin pages 11-13, thomas2015mutationsinsnx14 pages 1-3)
Zhang et al. National Science Review. “SNX14 deficiency-induced defective axonal mitochondrial transport in Purkinje cells … reversed by valproate.” Advance access 10 Feb 2021. https://doi.org/10.1093/nsr/nwab024 (zhang2021snx14deficiencyinduceddefective pages 1-2)
Zhou et al. JCI Insight. “Altered lipid homeostasis is associated with cerebellar neurodegeneration in SNX14 deficiency.” Published 16 Apr 2024. https://doi.org/10.1172/jci.insight.168594 (zhou2024alteredlipidhomeostasis pages 1-2)

References

(thomas2015mutationsinsnx14 pages 1-3): Anna C. Thomas, Hywel Williams, Núria Setó-Salvia, Chiara Bacchelli, Dagan Jenkins, Mary O’Sullivan, Konstantinos Mengrelis, Miho Ishida, Louise Ocaka, Estelle Chanudet, Chela James, Francesco Lescai, Glenn Anderson, Deborah Morrogh, Mina Ryten, Andrew J. Duncan, Yun Jin Pai, Jorge M. Saraiva, Fabiana Ramos, Bernadette Farren, Dawn Saunders, Bertrand Vernay, Paul Gissen, Anna Straatmaan-Iwanowska, Frank Baas, Nicholas W. Wood, Joshua Hersheson, Henry Houlden, Jane Hurst, Richard Scott, Maria Bitner-Glindzicz, Gudrun E. Moore, Sérgio B. Sousa, and Philip Stanier. Mutations in snx14 cause a distinctive autosomal-recessive cerebellar ataxia and intellectual disability syndrome. The American Journal of Human Genetics, 96:1008-1009, Jun 2015. URL: https://doi.org/10.1016/j.ajhg.2015.05.010, doi:10.1016/j.ajhg.2015.05.010. This article has 124 citations.
(akizu2015biallelicmutationsin pages 21-23): Naiara Akizu, Vincent Cantagrel, Maha S Zaki, Lihadh Al-Gazali, Xin Wang, Rasim Ozgur Rosti, Esra Dikoglu, Antoinette Bernabe Gelot, Basak Rosti, Keith K Vaux, Eric M Scott, Jennifer L Silhavy, Jana Schroth, Brett Copeland, Ashleigh E Schaffer, Philip L S M Gordts, Jeffrey D Esko, Matthew D Buschman, Seth J Field, Gennaro Napolitano, Ghada M Abdel-Salam, R Koksal Ozgul, Mahmut Samil Sagıroglu, Matloob Azam, Samira Ismail, Mona Aglan, Laila Selim, Iman G Mahmoud, Sawsan Abdel-Hadi, Amera El Badawy, Abdelrahim A Sadek, Faezeh Mojahedi, Hulya Kayserili, Amira Masri, Laila Bastaki, Samia Temtamy, Ulrich Müller, Isabelle Desguerre, Jean-Laurent Casanova, Ali Dursun, Murat Gunel, Stacey B Gabriel, Pascale de Lonlay, and Joseph G Gleeson. Biallelic mutations in snx14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Apr 2015. URL: https://doi.org/10.1038/ng.3256, doi:10.1038/ng.3256. This article has 161 citations and is from a highest quality peer-reviewed journal.
(akizu2015biallelicmutationsin pages 3-4): Naiara Akizu, Vincent Cantagrel, Maha S Zaki, Lihadh Al-Gazali, Xin Wang, Rasim Ozgur Rosti, Esra Dikoglu, Antoinette Bernabe Gelot, Basak Rosti, Keith K Vaux, Eric M Scott, Jennifer L Silhavy, Jana Schroth, Brett Copeland, Ashleigh E Schaffer, Philip L S M Gordts, Jeffrey D Esko, Matthew D Buschman, Seth J Field, Gennaro Napolitano, Ghada M Abdel-Salam, R Koksal Ozgul, Mahmut Samil Sagıroglu, Matloob Azam, Samira Ismail, Mona Aglan, Laila Selim, Iman G Mahmoud, Sawsan Abdel-Hadi, Amera El Badawy, Abdelrahim A Sadek, Faezeh Mojahedi, Hulya Kayserili, Amira Masri, Laila Bastaki, Samia Temtamy, Ulrich Müller, Isabelle Desguerre, Jean-Laurent Casanova, Ali Dursun, Murat Gunel, Stacey B Gabriel, Pascale de Lonlay, and Joseph G Gleeson. Biallelic mutations in snx14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Apr 2015. URL: https://doi.org/10.1038/ng.3256, doi:10.1038/ng.3256. This article has 161 citations and is from a highest quality peer-reviewed journal.
(bryant2018snx14mutationsaffect pages 1-2): Dale Bryant, Yang Liu, Sanchari Datta, Hanaa Hariri, Marian Seda, Glenn Anderson, Emma Peskett, Charalambos Demetriou, Sergio Sousa, Dagan Jenkins, Peter Clayton, Maria Bitner-Glindzicz, Gudrun E Moore, W Mike Henne, and Philip Stanier. Snx14 mutations affect endoplasmic reticulum-associated neutral lipid metabolism in autosomal recessive spinocerebellar ataxia 20. Human Molecular Genetics, 27:1927–1940, Jun 2018. URL: https://doi.org/10.1093/hmg/ddy101, doi:10.1093/hmg/ddy101. This article has 81 citations and is from a domain leading peer-reviewed journal.
(maia2020twocompoundheterozygous pages 1-2): Nuno Maia, Gabriela Soares, Cecília Silva, Isabel Marques, Bárbara Rodrigues, Rosário Santos, Manuel Melo-Pires, Arjan PM de Brouwer, Teresa Temudo, and Paula Jorge. Two compound heterozygous variants in snx14 cause stereotypies and dystonia in autosomal recessive spinocerebellar ataxia 20. Frontiers in Genetics, Sep 2020. URL: https://doi.org/10.3389/fgene.2020.01038, doi:10.3389/fgene.2020.01038. This article has 9 citations and is from a peer-reviewed journal.
(levchenko2023homozygousdeepintronic pages 1-2): Olga Levchenko, Alexandra Filatova, Irina Mishina, Aleksey Antonenko, and Mikhail Skoblov. Homozygous deep intronic variant in snx14 cause autosomal recessive spinocerebellar ataxia 20: a case report. Frontiers in Genetics, Jul 2023. URL: https://doi.org/10.3389/fgene.2023.1197681, doi:10.3389/fgene.2023.1197681. This article has 5 citations and is from a peer-reviewed journal.
(shao2024compoundheterozygousmutation pages 1-2): Yuqi Shao, Saisai Yang, Jiafu Li, Lin Cheng, Jiawei Kang, Juan Liu, Jianhong Ma, Jie Duan, and Yuanzhen Zhang. Compound heterozygous mutation of the snx14 gene causes autosomal recessive spinocerebellar ataxia 20. Frontiers in Genetics, Apr 2024. URL: https://doi.org/10.3389/fgene.2024.1379366, doi:10.3389/fgene.2024.1379366. This article has 2 citations and is from a peer-reviewed journal.
(akizu2015biallelicmutationsin pages 1-3): Naiara Akizu, Vincent Cantagrel, Maha S Zaki, Lihadh Al-Gazali, Xin Wang, Rasim Ozgur Rosti, Esra Dikoglu, Antoinette Bernabe Gelot, Basak Rosti, Keith K Vaux, Eric M Scott, Jennifer L Silhavy, Jana Schroth, Brett Copeland, Ashleigh E Schaffer, Philip L S M Gordts, Jeffrey D Esko, Matthew D Buschman, Seth J Field, Gennaro Napolitano, Ghada M Abdel-Salam, R Koksal Ozgul, Mahmut Samil Sagıroglu, Matloob Azam, Samira Ismail, Mona Aglan, Laila Selim, Iman G Mahmoud, Sawsan Abdel-Hadi, Amera El Badawy, Abdelrahim A Sadek, Faezeh Mojahedi, Hulya Kayserili, Amira Masri, Laila Bastaki, Samia Temtamy, Ulrich Müller, Isabelle Desguerre, Jean-Laurent Casanova, Ali Dursun, Murat Gunel, Stacey B Gabriel, Pascale de Lonlay, and Joseph G Gleeson. Biallelic mutations in snx14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Apr 2015. URL: https://doi.org/10.1038/ng.3256, doi:10.1038/ng.3256. This article has 161 citations and is from a highest quality peer-reviewed journal.
(akizu2015biallelicmutationsin pages 11-13): Naiara Akizu, Vincent Cantagrel, Maha S Zaki, Lihadh Al-Gazali, Xin Wang, Rasim Ozgur Rosti, Esra Dikoglu, Antoinette Bernabe Gelot, Basak Rosti, Keith K Vaux, Eric M Scott, Jennifer L Silhavy, Jana Schroth, Brett Copeland, Ashleigh E Schaffer, Philip L S M Gordts, Jeffrey D Esko, Matthew D Buschman, Seth J Field, Gennaro Napolitano, Ghada M Abdel-Salam, R Koksal Ozgul, Mahmut Samil Sagıroglu, Matloob Azam, Samira Ismail, Mona Aglan, Laila Selim, Iman G Mahmoud, Sawsan Abdel-Hadi, Amera El Badawy, Abdelrahim A Sadek, Faezeh Mojahedi, Hulya Kayserili, Amira Masri, Laila Bastaki, Samia Temtamy, Ulrich Müller, Isabelle Desguerre, Jean-Laurent Casanova, Ali Dursun, Murat Gunel, Stacey B Gabriel, Pascale de Lonlay, and Joseph G Gleeson. Biallelic mutations in snx14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Apr 2015. URL: https://doi.org/10.1038/ng.3256, doi:10.1038/ng.3256. This article has 161 citations and is from a highest quality peer-reviewed journal.
(zhang2021snx14deficiencyinduceddefective pages 1-2): Hongfeng Zhang, Yujuan Hong, Weijie Yang, Ruimin Wang, Ting Yao, Jian Wang, Ke Liu, Huilong Yuan, Chaoqun Xu, Yuanyuan Zhou, Guanxian Li, Lishan Zhang, Hong Luo, Xian Zhang, Dan Du, Hao Sun, Qiuyang Zheng, Yun-Wu Zhang, Yingjun Zhao, Ying Zhou, Huaxi Xu, and Xin Wang. Snx14 deficiency-induced defective axonal mitochondrial transport in purkinje cells underlies cerebellar ataxia and can be reversed by valproate. National Science Review, Feb 2021. URL: https://doi.org/10.1093/nsr/nwab024, doi:10.1093/nsr/nwab024. This article has 27 citations and is from a peer-reviewed journal.
(thomas2015mutationsinsnx14 pages 3-5): Anna C. Thomas, Hywel Williams, Núria Setó-Salvia, Chiara Bacchelli, Dagan Jenkins, Mary O’Sullivan, Konstantinos Mengrelis, Miho Ishida, Louise Ocaka, Estelle Chanudet, Chela James, Francesco Lescai, Glenn Anderson, Deborah Morrogh, Mina Ryten, Andrew J. Duncan, Yun Jin Pai, Jorge M. Saraiva, Fabiana Ramos, Bernadette Farren, Dawn Saunders, Bertrand Vernay, Paul Gissen, Anna Straatmaan-Iwanowska, Frank Baas, Nicholas W. Wood, Joshua Hersheson, Henry Houlden, Jane Hurst, Richard Scott, Maria Bitner-Glindzicz, Gudrun E. Moore, Sérgio B. Sousa, and Philip Stanier. Mutations in snx14 cause a distinctive autosomal-recessive cerebellar ataxia and intellectual disability syndrome. The American Journal of Human Genetics, 96:1008-1009, Jun 2015. URL: https://doi.org/10.1016/j.ajhg.2015.05.010, doi:10.1016/j.ajhg.2015.05.010. This article has 124 citations.
(kim2021twokoreansiblings pages 3-4): Ae Ryoung Kim, Jong-Mok Lee, Go Hun Seo, Sang In Lee, Hyunwoo Bae, and Yun Jeong Lee. Two korean siblings with autosomal recessive spinocerebellar ataxia 20 caused by homozygous variants in snx14. Journal of Genetic Medicine, 18:127-131, Dec 2021. URL: https://doi.org/10.5734/jgm.2021.18.2.127, doi:10.5734/jgm.2021.18.2.127. This article has 1 citations.
(thomas2015mutationsinsnx14 media ca718e7a): Anna C. Thomas, Hywel Williams, Núria Setó-Salvia, Chiara Bacchelli, Dagan Jenkins, Mary O’Sullivan, Konstantinos Mengrelis, Miho Ishida, Louise Ocaka, Estelle Chanudet, Chela James, Francesco Lescai, Glenn Anderson, Deborah Morrogh, Mina Ryten, Andrew J. Duncan, Yun Jin Pai, Jorge M. Saraiva, Fabiana Ramos, Bernadette Farren, Dawn Saunders, Bertrand Vernay, Paul Gissen, Anna Straatmaan-Iwanowska, Frank Baas, Nicholas W. Wood, Joshua Hersheson, Henry Houlden, Jane Hurst, Richard Scott, Maria Bitner-Glindzicz, Gudrun E. Moore, Sérgio B. Sousa, and Philip Stanier. Mutations in snx14 cause a distinctive autosomal-recessive cerebellar ataxia and intellectual disability syndrome. The American Journal of Human Genetics, 96:1008-1009, Jun 2015. URL: https://doi.org/10.1016/j.ajhg.2015.05.010, doi:10.1016/j.ajhg.2015.05.010. This article has 124 citations.
(akizu2015biallelicmutationsin pages 4-6): Naiara Akizu, Vincent Cantagrel, Maha S Zaki, Lihadh Al-Gazali, Xin Wang, Rasim Ozgur Rosti, Esra Dikoglu, Antoinette Bernabe Gelot, Basak Rosti, Keith K Vaux, Eric M Scott, Jennifer L Silhavy, Jana Schroth, Brett Copeland, Ashleigh E Schaffer, Philip L S M Gordts, Jeffrey D Esko, Matthew D Buschman, Seth J Field, Gennaro Napolitano, Ghada M Abdel-Salam, R Koksal Ozgul, Mahmut Samil Sagıroglu, Matloob Azam, Samira Ismail, Mona Aglan, Laila Selim, Iman G Mahmoud, Sawsan Abdel-Hadi, Amera El Badawy, Abdelrahim A Sadek, Faezeh Mojahedi, Hulya Kayserili, Amira Masri, Laila Bastaki, Samia Temtamy, Ulrich Müller, Isabelle Desguerre, Jean-Laurent Casanova, Ali Dursun, Murat Gunel, Stacey B Gabriel, Pascale de Lonlay, and Joseph G Gleeson. Biallelic mutations in snx14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Apr 2015. URL: https://doi.org/10.1038/ng.3256, doi:10.1038/ng.3256. This article has 161 citations and is from a highest quality peer-reviewed journal.
(akizu2015biallelicmutationsin pages 13-21): Naiara Akizu, Vincent Cantagrel, Maha S Zaki, Lihadh Al-Gazali, Xin Wang, Rasim Ozgur Rosti, Esra Dikoglu, Antoinette Bernabe Gelot, Basak Rosti, Keith K Vaux, Eric M Scott, Jennifer L Silhavy, Jana Schroth, Brett Copeland, Ashleigh E Schaffer, Philip L S M Gordts, Jeffrey D Esko, Matthew D Buschman, Seth J Field, Gennaro Napolitano, Ghada M Abdel-Salam, R Koksal Ozgul, Mahmut Samil Sagıroglu, Matloob Azam, Samira Ismail, Mona Aglan, Laila Selim, Iman G Mahmoud, Sawsan Abdel-Hadi, Amera El Badawy, Abdelrahim A Sadek, Faezeh Mojahedi, Hulya Kayserili, Amira Masri, Laila Bastaki, Samia Temtamy, Ulrich Müller, Isabelle Desguerre, Jean-Laurent Casanova, Ali Dursun, Murat Gunel, Stacey B Gabriel, Pascale de Lonlay, and Joseph G Gleeson. Biallelic mutations in snx14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Apr 2015. URL: https://doi.org/10.1038/ng.3256, doi:10.1038/ng.3256. This article has 161 citations and is from a highest quality peer-reviewed journal.
(kim2021twokoreansiblings pages 1-3): Ae Ryoung Kim, Jong-Mok Lee, Go Hun Seo, Sang In Lee, Hyunwoo Bae, and Yun Jeong Lee. Two korean siblings with autosomal recessive spinocerebellar ataxia 20 caused by homozygous variants in snx14. Journal of Genetic Medicine, 18:127-131, Dec 2021. URL: https://doi.org/10.5734/jgm.2021.18.2.127, doi:10.5734/jgm.2021.18.2.127. This article has 1 citations.
(bryant2018snx14mutationsaffect pages 10-10): Dale Bryant, Yang Liu, Sanchari Datta, Hanaa Hariri, Marian Seda, Glenn Anderson, Emma Peskett, Charalambos Demetriou, Sergio Sousa, Dagan Jenkins, Peter Clayton, Maria Bitner-Glindzicz, Gudrun E Moore, W Mike Henne, and Philip Stanier. Snx14 mutations affect endoplasmic reticulum-associated neutral lipid metabolism in autosomal recessive spinocerebellar ataxia 20. Human Molecular Genetics, 27:1927–1940, Jun 2018. URL: https://doi.org/10.1093/hmg/ddy101, doi:10.1093/hmg/ddy101. This article has 81 citations and is from a domain leading peer-reviewed journal.
(datta2020snx14proximitylabeling pages 1-2): Sanchari Datta, Jade Bowerman, Hanaa Hariri, Rupali Ugrankar, Kaitlyn M. Eckert, Chase Corley, Gonçalo Vale, Jeffrey G. McDonald, and W. Mike Henne. Snx14 proximity labeling reveals a role in saturated fatty acid metabolism and er homeostasis defective in scar20 disease. Dec 2020. URL: https://doi.org/10.1073/pnas.2011124117, doi:10.1073/pnas.2011124117. This article has 28 citations and is from a highest quality peer-reviewed journal.
(zhou2024alteredlipidhomeostasis pages 1-2): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.
(zhou2024alteredlipidhomeostasis pages 17-18): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.
(akizu2015biallelicmutationsin pages 6-8): Naiara Akizu, Vincent Cantagrel, Maha S Zaki, Lihadh Al-Gazali, Xin Wang, Rasim Ozgur Rosti, Esra Dikoglu, Antoinette Bernabe Gelot, Basak Rosti, Keith K Vaux, Eric M Scott, Jennifer L Silhavy, Jana Schroth, Brett Copeland, Ashleigh E Schaffer, Philip L S M Gordts, Jeffrey D Esko, Matthew D Buschman, Seth J Field, Gennaro Napolitano, Ghada M Abdel-Salam, R Koksal Ozgul, Mahmut Samil Sagıroglu, Matloob Azam, Samira Ismail, Mona Aglan, Laila Selim, Iman G Mahmoud, Sawsan Abdel-Hadi, Amera El Badawy, Abdelrahim A Sadek, Faezeh Mojahedi, Hulya Kayserili, Amira Masri, Laila Bastaki, Samia Temtamy, Ulrich Müller, Isabelle Desguerre, Jean-Laurent Casanova, Ali Dursun, Murat Gunel, Stacey B Gabriel, Pascale de Lonlay, and Joseph G Gleeson. Biallelic mutations in snx14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Apr 2015. URL: https://doi.org/10.1038/ng.3256, doi:10.1038/ng.3256. This article has 161 citations and is from a highest quality peer-reviewed journal.
(kim2021twokoreansiblings pages 4-5): Ae Ryoung Kim, Jong-Mok Lee, Go Hun Seo, Sang In Lee, Hyunwoo Bae, and Yun Jeong Lee. Two korean siblings with autosomal recessive spinocerebellar ataxia 20 caused by homozygous variants in snx14. Journal of Genetic Medicine, 18:127-131, Dec 2021. URL: https://doi.org/10.5734/jgm.2021.18.2.127, doi:10.5734/jgm.2021.18.2.127. This article has 1 citations.

Ask OpenScientist

OpenScientist Report

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Comprehensive Research Report: Lichtenstein–Knorr Syndrome (SNX14-related SCAR20)

Executive summary

1. Disease information

1.1 Definition and current understanding

1.2 Key identifiers and nomenclature

1.3 Evidence source type

2. Etiology

2.1 Primary causal factors

2.2 Risk factors

2.3 Protective factors / gene–environment interactions

3. Phenotypes

3.1 Core phenotype spectrum (with frequencies where available)

3.2 Onset and progression

3.3 Quality-of-life / functional impact

3.4 Suggested HPO terms

4. Genetic / molecular information

4.1 Causal gene and inheritance

4.2 Pathogenic variant classes and examples

4.3 Functional consequence (current consensus)

4.4 Modifier genes / epigenetics

5. Environmental information

6. Mechanism / pathophysiology

6.1 Lysosome–autophagosome dysfunction (human cells and zebrafish)

6.2 ER–lipid droplet contact biology and lipid homeostasis (cell biology)

6.3 Selective cerebellar vulnerability and lipidomic signatures (2024 JCI Insight)

6.4 Axonal microtubule organization and mitochondrial transport; pharmacologic rescue (2021 mouse models)

6.5 Causal chain (integrated view)

6.6 Ontology suggestions (mechanism annotation)

7. Anatomical structures affected

7.1 Primary organs/systems

7.2 Neuroimaging corroboration (with figure evidence)

8. Temporal development (natural history)

8.1 Onset

8.2 Progression

9. Inheritance and population

9.1 Epidemiology

9.2 Consanguinity and founder effects

10. Diagnostics

10.1 Clinical suspicion and imaging

10.2 Genetic testing strategy and real-world implementation

10.3 Differential diagnosis considerations

11. Outcome / prognosis

12. Treatment

12.1 Current standard of care (evidence in retrieved sources)

12.2 Experimental / emerging therapy signals

12.3 Suggested MAXO terms (management annotation; suggested)

13. Prevention

14. Other species / natural disease

15. Model organisms

15.1 Zebrafish